arrow
O

Olaf Penack

Charité - Universitätsmedizin Berlin
H指数:56
被引数:9,245

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lung transplantation after allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT

同种异基因造血干细胞移植后的肺移植:EBMT移植并发症工作组的研究

2026-10-260
PRE
GvHD prophylaxis in elderly patients: post-transplant cyclophosphamide or ATG? A study by the EBMT transplant complications working party

老年患者移植排斥反应预防:移植后环磷酰胺还是抗胸腺细胞球蛋白?EBMT移植并发症工作组研究

2026-10-060
PRE
Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GVHD: results from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP

ROCK2抑制剤belumosudil对慢性GVHD的疗效与安全性:来自belumosudil MAP大型德奥人群多中心回顾性分析的结果

2026-10-050
PRE
Correction: Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT transplant complications and autoimmune diseases working parties

更正:异基因造血干细胞移植后的继发性自身免疫性和炎症性疾病:来自EBMT移植并发症和自身免疫性疾病工作组的事后研究

2026-09-250
PRE
Pre–CAR-T B-cell–directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis

CD19 CAR-T治疗前B细胞靶向免疫治疗暴露及大B细胞淋巴瘤患者接受CD19 CAR-T治疗后结局:一项EBMT登记研究

2026-09-010
OAAI
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
Leukemia
IF13.4
2026-08-310
OA
Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland – part II – expert based recommendations for surveillance and management of side-effects

德国、奥地利和瑞士关于使用onasemnogene abeparvovec进行脊髓性肌萎缩基因治疗的德尔菲共识——第二部分——基于专家的建议:副作用监测和管理

2026-08-270
PRE
CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial

CD19 CAR T细胞疗法治疗难治性血清阳性类风湿关节炎:一项1期临床试验

2026-08-270
PRE
Fecal microbiota transplantation in the treatment of acute graft-versus-host disease: A retrospective study performed by the Complications Working Party and Pediatric Diseases Working Party of the EBMT

粪菌移植在急性移植物抗宿主病治疗中的应用:EBMT并发症工作组与儿科疾病工作组开展的一项回顾性研究

2026-08-180
PRE
Secondary autoimmune and inflammatory diseases after allogeneic hematopoietic stem cell transplantation: a retrospective study from the EBMT transplant complications and autoimmune diseases working parties

异基因造血干细胞移植后的继发性自身免疫性和炎症性疾病:来自EBMT移植并发症和自身免疫性疾病工作组的事后研究

2026-07-270
PRE
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells

克隆性造血不影响嵌合抗原受体(CAR)T细胞的制备

2026-06-030
OAAI
The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

2024年EBMT活动报告:完成一百万例HCT和2万例CAR-T。细胞疗法的重要里程碑

2026-05-270
OAAI
Central nervous system complications after allogeneic haematopoietic cell transplantation: best practice recommendations from the EBMT practice harmonisation and guidelines committee on epidemiology, outcome and neuroimaging

异基因造血细胞移植后的中枢神经系统并发症:EBMT实践协调和指南委员会关于流行病学、结局和神经影像学的最佳实践建议

2026-05-130
PRE
Symptom-guided approach to central nervous system complications in allogeneic hematopoietic cell transplant recipients: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines committee

症状指导方法在异基因造血细胞移植受者中枢神经系统并发症中的应用:EBMT实践协调和指南委员会的最佳实践建议

2026-05-070
PRE
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

德国和瑞士常规环境中,Brexucabtagene-autoleucel治疗复发/难治性套细胞淋巴瘤患者的疗效结果

2026-01-160
OAAI
Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide—A Prospective Study on Behalf of the EBMT Transplant Complications Working Party

haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide的并发症——EBMT移植并发症工作组发起的一项前瞻性研究

2025-12-180
OAAI